CAI Caris Life Sciences (CAI) Q2 FY26 earnings call
Caris Life Sciences delivered a strong Q2 FY26, marked by record clinical volume and robust financial performance, driven by the successful realignment of its commercial strategy. The company's comprehensive molecular profiling platform continues to expand with new product launches, including Caris Detect for multi-cancer early detection and MIClarity V2, alongside pipeline advancements in MRD. This financial strength enables significant investment in capacity and product development, supporting a raised full-year revenue outlook despite potential near-term capacity constraints for new offerin
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
CAI operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | This call Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Covered lives MI Cancer Seek | 225M+The key driver for tissue was obviously the impact from our FDA approval and the subsequent increase in pricing and the benefits we saw through contract, where we have now surpassed over 225 million covered lives from MI Cancer Seek.Source: earnings call transcript | 225M+At this point, we're above $225 million covered lives for MI Cancer Seek, which we expect to continue to increase throughout the course of this year, and the assay represented more than 75% of our tissue volume in Q1.Source: earnings call transcript | ~239.5MWith regard to covered lives that now stands at approximately $239.5 million for MI Cancer Seq and $131.9 million for Care Assure and is a testament to the great work by our market access teams as we continue to see improvements across the payer landscape.Source: earnings call transcript | — |
| Procedures | — | 52.8KIn the first quarter, we completed 52,800 cases, up 15% year-over-year.Source: earnings call transcript | 59.2KWe added roughly 6,400 cases in the quarter, a record for sequential case additions that led us to 59,200 cases.Source: earnings call transcript | +12.1% |
| Procedures Tissue | — | ~43.6KFor Q1 overall, we completed approximately 52,800 therapy selection cases, up 15% year-over-year, including approximately 43,600 tissue cases and approximately 9,200 Caris Assure cases.Source: earnings call transcript | ~48.3KWith respect to performance by product, we completed approximately 48,300 MI profile tissue cases, up 13% year-over-year and 11% sequentially and 10,700 Caris Assure blood cases up 50% year-over-year and 17% sequentially.Source: earnings call transcript | — |
| Procedures Caris Assure | — | ~9,200For Q1 overall, we completed approximately 52,800 therapy selection cases, up 15% year-over-year, including approximately 43,600 tissue cases and approximately 9,200 Caris Assure cases.Source: earnings call transcript | 10.7KWith respect to performance by product, we completed approximately 48,300 MI profile tissue cases, up 13% year-over-year and 11% sequentially and 10,700 Caris Assure blood cases up 50% year-over-year and 17% sequentially.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.